RHEUMATIC DISEASE CLINICS OF NORTH AMERICA Rheum Dis Clin N Am 28 (2002) 1003 1030 Cumulative Index 2002 Volume 28 February GENETICS, pages 180 May REGIONAI MANAGEMENT )F FIBROMYALGIA pages 18] 460 August PEDIATRIC RHEUMATOLOGY pages 461 745 November IDIOPATHIC INFLAMMATORY MYOPATHIES pages 1030 Page numbers of articl in bold face ty \ Alendronate for osteoporosis Acanthosis nigricans. in de n juvenile rheumatoid arthritis, n pediatric rheumatic diseases Acetaminophen, for syndrome 268 Alkaline phosphatase, bone-specific netabolism marker 655 Acid maltase deficiency of. 76 Allodynia n fibromyalgia syndrome, 235 Activities of daily living, asse in pediatric patients, 671 n Horror ny ilgia syndrome in inflammatory myopatt Alprazolam, for fibromyalgia syndrome, 266. 426 Acupuncture, for Hdromyaigia 300 358 \lternative marker-disease association hypothesis, in rheumatoid arthritis, 40 S-Aden sylmethionine, for syndrome 266 Alternative therapy, for fibromyalgia syndrome, 300-301 Adhesion molecu mvopathy Alveolitis fibrosing, in inflammatory ysfunctior myopathy, 832 39] 394 in inflammatory myopathy, 992—993 Adrenocorticotropic hormone Amantadine, for fibromyalgia syndrome, 373 fibromyalgia syndrome American College of Rheumatology, juvenile A erobi ¢ condition rheumatoid arthritis classification of, syndrome, 42 503-504 A ffec ed sibling pair studies Aminoacyl-tRNA Sy nthetases antibodies arthritis, 3, 7—9 to, myopathy and, 814 816, 834, itive disorders 994-995 in fibromyalgia syndrome Amitriptyline, for fibromyalgia syndrome, 245, substance P inhibitors for 273-274 277 —278. 371 Alanine aminotransferase measul exercise implications of, 424 of, in inflammatory my opatt in fatigue, 266 SHO SO in sleep disorders, 359 Aldolase, measurement of, in nmatory Amyloid deposition, in inflammatory myopathy, 866 myopathy, 793—794 O889-857X/02/8 see front matter 2002 Elsevier Science (USA) All rights reserved PI SO889-857X(02)00095-9 1004 Cumulative Index 2002 / Rheum Dis ¢ 1m 28 (2002) 1003-1030 Amyopathic dermatomyositis, 833 — 834 An tisynthase antibodies in inflammatory familial 894 myopathy, 868, 873 R78 juvenile R53 854 tisynthetase syndrome, 814-816, 834 Anakinra, for pediatric rheumatic diseases, 4 994 995 Androgens, fibromyalgia syndrome related to © inflammatory myopathy, 991 396 39 sleep, in fibromyalgia syndrome, 189 Anemia 361 —362 in fibromyalgia syndrome 36 in Kawasaki disease, 631 —632 | oprote! I defects of in inflammatory yopathy SYK — 899 Aneurysms, coronary artery, in Kawasaki disease 6342 -634> Art eritis, Takayasu's, in pediatric patients 6 r¢ 6 Anguitis primary of central nervous system. 6) 7 692 in inflammatory myopaIt hy, 833 % Angiography, in vasculitis, 6 nthesitis-related, 506 Animal models yositis. See Myositis Churg-Strauss syndrome, 64 inimal models of Henoch-Schénlein purpura, 639 venile dermatomyositis, 851 Ankylosing spondylitis, juvenile-onset Kawé isaki disease, 631 544 spondyloarthritides $345 427 Ankylosing tarsitis emic lupus erythematosus, 565 venile-onset, 506 Antibiotics for spondyloarthritides Antibody(ies). See Autoar bodies heumatoid, juvenile. See J specific antibodies umatoid arthritis inflammatory myopath versus juvenile rheumatoid synthetase, myopathy in urthritis, 509-512 Anticardiolipin antibodies lic peptides, in rheumatoid erythematosus, 569 minotransterase, measurement of Antidepressants, for fibrom) inflammatory myopathy, 866-867 189 275, 441-442 implications of fatigue component, 37 Kawasaki disease 465 — 466 634 1 mood disorders, 27 Q pediatric rheumatic diseases, 46 466 244-247 studies, in rheumatoid arthritis disorders S21 Antiepileptic drugs lor fibromyalgiz Ast hma n Churg-Strauss syndrome, 647 syndrome 248 249 itoantibodies Antineoplastic agents, tumor susceptibility to vopathy, 814-816 transcript array analysis of, 166 994995 Antineutrophil cytoplasmic antibodies scleroderma, 609-610 in Churg-Strauss syndrome, 646-64 syst emic lupus erythematosus, 564 n systemic sclerosis, 681 iinn mHiecnroocshc-oSpcich énlpoeliynan gipiutripsu,r a, 6466 42 sculitis, 62>32 624 in Wegener's granulomatosis, 644-646 \ itoimmune disorders ibromyalgia syndrome, 409, 414 Antinuclear antibodies inflammatory myopathy 728—729 in dermatomyositis, 586 in fibromyalgia syndrome, 21 3 214 AL itonomic ner vous system ’ idiopathic musculoskeletal pain, 673 disorderso f. See Dysautonomia in inflammatory myopathy, 871 evaluation of, 380 383 n systemic lupus erythematosus, 569 function of, 3 79 380 Antispasticity agents, for fibromyalgia AN ascular necrosis, in systemic lupus syndrome, 249 erythematosus, 568 Cumulative im 28 (2002) 1003-1030 Azathioopr riinnef lammatory myopat! juvenil6eH5 8— rhe6u6m1 a, toid arthritis OR7 990. 993 normal growth, 656—65 for pediatric rheumatic dis an, in idiopathic musculoskeletal Henoch-Schénlein pI ain. 6 uvenile rheumatoid ystemic lupus ec! motility disorders, substance P S61 S462 inhibitors for pain transmission in, in fibromyalgia B syndrome, 187 B lymphocytes, trat ystemic lupus erythematosus 159— 160 manifestations in 563-565 Back pain Brancher deficiency, clinical features of, 767 Baclot Breast cancer, transcript array analysis of 164-165 Balance 1azepam, for fibromyalgia syndrome, 266 choalveol vag n inflammatory myopathy 053 Bupropion, for fibromyalgia syndrome 247 § 979 yndrome tibron myositis induction, 925-926 yndrome, 279 529~—59] Calcitonin for fibromyalgia syndrome, 266 for osteoporosis, In systemic lupus erythematosus, 56 osteoporosis n juvenile rheumatoid arthritis, 518 van an. d Poeott er cl| assifir r in pediatric rheumatic diseases inflammatory 656-657 systemic lupus erythematosus, 567 bone. 653 diseases, 463 of. See ( steoporos ter infections, reactive arthritis in, metabolism of, in pedi diseases, 653-665 Ostec yPOTOSIS biochemical markers ¢ in inflammatory myopathy, 729 bone density meas in juvenile dermatomyositis, 853 65 658 myositis in, 833 bone function and composi transcript array analysis of, 162—166 653-654 versus juvenile rheumatoid arthritis, cellular elements 510-513 1006 Cumulative Index 2002 /R heum Dis Clin N Am 28 (2002) 1003—1030 Candidate gene approach, to susceptibility Childhood Health Questionnaire, in loci search inflammatory myopathy, 967 in osteoarthritis, 103-105 . < Childhood Myositis Assessment Scale, in rheumatoid arthritis, 5 —6 A 946 94 Capillary vasculopathy " 7 : — Chimerism, in inflammatory myopathy, 89 in inflammatory myopathy, 813-814 della ’ nailfold, in dermatomyositis, 844-846 Chiropractic, for fibromyalgia syndrome, 300 Carbidopa/levodopa, for fibromyalgia Chlamydia infections, reactive arthritis in, 542 syndrome, 425 Chlorambucil, for inflammatory Carbohydrate metabolism, in myopathies, myopathy, 989 759~—764 Chlorpromazine, for fibromyalgia Carbonic anhydrase II1, measurement of, in syndrome, 360 inflammatory myopathy, 866—867 Chondrocytes, gene therapy directed to, in Cardiovascular disorders, in Kawasaki disease rheumatoid arthritis, 141 — 142 632»2 -633 Chromosomes, shortening of, by telomerase Carisoprodol, for fibromyalgia syndrome activity, in rheumatoid arthritis, 86—87 278, 425 Chronic fatigue syndrome, fibromyalgia Camitine deficiency, myopathy in syndrome overlap with. See Fatigue, in , fibromyalgia syndrome Carpal tunnel syndrome, in fibromyalgia . syndrome, 313 Churg-Strauss syndrome, in pediatric patients 646 —-647 cDNA, in transcript array analysis See Transcript array analysis Ciguatera poisoning, myositis in, 904 Central nervous system. See also Brain Circadian pacemaker, in fibromyalgia Spinal cord syndrome, 398 — 399 Henoch-Schénlein purpura / manifestations in, 640 Citalopram, for fibromyalgia syndrome, 246, pain pathways in, 236-244 266, 274, 371 primary angiitis of, 627—628 CJ-11974 (substance P inhibitor), for systemic lupus erythematosus fibromyalgia syndrome. 339 manifestations in, 563-565 ‘ Clodronate, for osteoporosis, in pediatric entral sensitivity syndromes, in fibromyalgia rheumatic diseases, 471 syndrome, 193, 206, 280, 421 Clonazepam, for fibromyalgia syndrome hagas’ disease, inflammatory myopathy 277-278. 413-414 in, 908 exercise implications of, 425 in slee rders. 189 >3 61. 385 hemokines, in inflammatory myopathy, 809, n sleep disorders, 189, R11—R813 Clonidine, for fibromyalgia syndrome, 249 he» mother. apy tumor suscep. tibililtiyty to Coegnitive-behavioral therapy, for f. ibromyalgia transcript array analysis of, 166 syndrome, 443 hest pain, in f. ibromyalgia syndrome inn Tatifagtiugeue comcor ponen1et , <2 98 408409. 413 in sleep disorders, 358 hiari malformation, f; ibromyalgj ia syndrome Cogmgintiiti ve dnsd,y ssfft unctiony with, 211-212 in. fibromyalgia syndrome,. 191011 , 205, 282 hilblains, musculoskeletal pain in, 676 in systemic lupus erythematosus, 564 hildhood Arthritis Health Profile, 515 COL genes, mutations of, in osteoarthritis, hildhood Health Assessment 101-107 Questionnaire, 495 Colchicine, for dermatomyositis, 994 in inflammatory myopathy, 947-948, 964 Cold intolerance, in fibromyalgia syndrome, in juvenile rheumatoid arthritis, 5 193, 282 Cumulative Index 2002 / Rheum in N Am 28 (2002) 1003—1030 1007 Collagen CP122721 (substance P inhibitor), for nausea bovine, inflammatory myopathy related j and vomiting, 336 to. 904 degradation products of, as | reatine, measurement of, in inflammatory metabolism markers myopathy, 867, 871 in bone, 654 reatine kinase, measurement of in inflammatory myopathy, 733-734 ompartment syndrome, chronic 863 —866, 949-950 musculoskeletal pain in, 676 in metabolic myopathy, 769 omplement deficiency, systen rohn's disease, arthropathy of, 545-546 erythematosus in, 570 ubital tunnel syndrome, in fibromyalgia omplementary and alternative therapy, for syndrome, 313 fibromyalgia syndrome, 300-301 yclobenzaprine, for fibromyalgia syndrome omplex regional pain syndrome 245, 266, 371 in fibromyalgia syndrome, 408 - 409, 414 prognosis for, 679 exercise implications of } sleep disorders, 8 omputed tomography yclophosphamide in systemic lupus erythe for inflammatory myopathy, 989, 993 lung, in inflammatory for pediatric rheumatic diseases, 467 quantitative, in bone de 473-474 measurement, 658 Henoch-Schénlein purpura, 644 ontinuous positi uvenile rheumatoid arthritis, 523 disorders, in fibromyalg icroscopic polyangiitis, 646 polyarteritis nodosa, 637 oping, with arthritis systemic lupus erythem oronary arte 561 —563 disease systemic s Wegener's 1ulomat orticosteroids for fibromyalgia sy1 osporine for inflammatory m\ © inflammatory myopathy, 989, 993 9R6— 9R7 for juvenile r}h eumatoid arthritis, 522 > dermatomy for pediatric rheumatic diseases, 467, 475 tric rheumatic di for spondyloarthritides, 548 —5 49 natomyositis interstitial, in fibromy yndrome Henoch-Sch6nl 410, 414 642 —643 uvenile rheumatoic " See §19—520 for, in rheumatoid arthritis, 82 Kawasaki disease, 635 SX — RY polyarteritis nodosa, ¢ n dermatomyositis, spondyloarthritides hypothalamic-pituitary-adrenal axis systemic lupus erythe regulation, fibromyalgia syndrome osteopenia due nI er’s granulon matory myopathy, 797, 799 645 — 646 ROO. X11] 3 RIX. ROR—ROO orticotropin releasing hom oO in scleroderma produced by T helper cells romyalgia syndror inflammation, 156—159 ortisol deficiency, in fibrom 391 —394 ostochondritis, in fibromyalgia syndrome, 310 Deconditioning, in fibromyalgia syndrome, exercise for, 190—191] oxsackievirus for myositis induction, 927 Dehydroepiandrosterone, fibromyalgia juvenile dermatomyositis and, 584 syndrome related to, 396—39 1008 Cumulative Index 2002 / Rheum Dis Clin N Am 28 (2002) 1003—1030 Dendritic cells Dolasetron, for fibromyalgia syndrome, for myositis induction, 926 320 transcript array analysis of, 160—161 L-Dopa/carbidopa, for fibromyalgia Depression, in fibromyalgia syndrome, syndrome, 189 189-190, 278-279 Dorsal horn neurons, pain transmission in, Dermatomyositis in fibromyalgia syndrome, 186—187 amyopathic, 833-834, 894 237-240 animal modelso f. See Myositis, animal for fibromyalgia syndrome, 245, models of 4,278 arthralgia in, 833 autoantibodies in. See Inflammatory Drug(s), inflammatory myopathy related to, myopathy(ies), autoantibodies in 902-904 calcinosis in, 831 cancer in, 729 Dual-ene X-ray absorptiometry, for clinical features of, 82 osteopenia, 657-658 diagnostic criteria for in systemic lupus erythematosus, 567 epidemiology of, 727 Duchenne muscular dystrophy familial, 894 expression profiling in, 751 —755 histochemistry of, 791 versus inflammatory myopathy, immunopathology of, 792 746—747, 749-750, 753 56 juvenile. See Juvenile dermatomyositis pathology of, + &? "oR5f. 7R9 ae9? Dysautonomia rpauslhm oinn,a ry8 27—in8v3o1l,v em9e9n3t- 99in,4 832 in fibraosmsyeaslsgmiean t syonf,d ro3m8e0,- 382208312 , 379-387 ulcerative course, 848 — 849 circadian disturbance, 356 weakness in, 832 pathophysiology of, 379-380, 383—3R4 Dermatomyositis sine myositis, 833-834 treatment of, 190, 384-385 Desipramine, for fibromyalgia syndrome, 274 in idiopathic musculoskeletal pain, 671 Desquamation, in Kawasaki disease, 631 ysferlin deficiency, myopathy in, versus Dextromethorphan, for fibromyalgia mmatory myopathy, 744-747 syndrome, 344-345, 347-348 Diaphyseal dysplasi progressive musculoskeletal pain in, 67¢ spepsia, nonulcer, in fibromyalgia Diclofenac, for pediatric rheumatic di S yndrome, 409 465 — 466 ysphagia Diet, inflammatory myopathy relatedt n inflammatory myopathy, 832-8 33 902 —904 951 —952. 983-984, 994 uvenile dermatomyositis, 850 Diltiazem, for dermatomyositis, 994 Dysphoria, in fibromyalgia syndrome, Diphenhydramine, for fibromyalgia 1727979 syndrome, 359 Dyspnea, in inflammatory myopathy, 832 Dipyridamole, for Henoch-Schénlein purpura, 644 ystrophic myopathy, versus inflammatory myopathy, 743-758 Discoid lupus dysferlin deficiency, 744 Dizziness, in fibromyalgia syndrome, dystrophinopathy, 746 281 —282 53-756 expression profiling in, 751, 753 DNA merosin deficiency, 747-748, 75¢ antibodies to, in systemic lupus erythematosus, 569 in transcript array analysis. See Transcript array analysis Echocardiography, in inflammatory myopathy, naked, for myositis induction, 926—927 953-954 Cumulative Index 2002 / Rheum Dis Clin N Am 28 (2002) 1003-1030 1009 Echoviruses, inflammatory my t related Environmental factors to, 906 in inflammatory myopathy, 900-909 dietary supplements, 902-904 Education drugs, 902-904 in transitions for child epidemiology and, 900-902 health care needs ¢ food. 902 —904 691-696 fibromvalg svn infections, 905 —909 Siri bg 00 vaccination, 904 296. 368 . car in juvenile dermatomyositis, 582—583 in rheumatoid arthritis, 4 osinophilia, in Churg-Strauss syndrome, 647 fectroacupuncture , a ” Eosinophilia myalgia syndrome, 903 —904 syndrome, 300 _ phalograph — ysinophilic fasciitis, versus systemic lectroencephalography, in sleep disor fibromyalgia syndrome scclleerroo sis 68?2 picondylitis, in fibromyalgia syndrome 307. 309 pistasis (gene-gene interactions), in Microscopy rheumatoid arthritis, 72 myopathy, 774 pstein-Barr virus infection, systemic lupus erythematosus and, 568 tional reactions, in fidron ndrome. 270 ythema, in dermatomyositis, 829, 846-84 n transitions rythromelalgia, musculoskeletal pain in, 676 health care ne 676 n inflammatory myopathy, 833 sabr—e, in sc juvenile dermatomyositis, 850 602 —604 yysstteemmi c sclleerro sis, 6]9 17. 688 | ndocrine dysfunction, in fibre syndrome, 190, 389-404 or juven9 il_e «9r2h eumatoid arthritis growth hormone insulin liatric rheumatic diseases, 467 factor-| axis, 395 472-473 hypothalamic-pituitary 39 394 for spondyloarthritides, 548 —5 49 melatonin 39& — 399 Ethnic differences, in rheumatoid arthritis modelo f. 389—390 19-20. 42-45 prolactin, 398 shared epitope hypothesis and, 62-67 sex hormones. 396 thWyrrOolimdW.d 35 94395 5 European Spondyloarthropathy Study Group, criteriao f, 534—535 ndomysial inflammation myopathy. 784. 786 for fibromyalgia syndrome, 190—191, ndothelial markers, for inflammatory 298. 370. 419-436 myopathy, 956—961 aerobic conditioning in, 428-429 ta M LIUOVET se ae balance improvement, 430, 432 If¢o r mmyyoossiitti s minaduuccttiioon,n 9I2 endocrine function and, 399—400 in inflammatory myopathy evaluation for, 422 flexibility training in, 429-430 Enthesitis 32-434 in arthritis, 506 individualization of, 422 in spondyloarthritides, 53 3 interventions for, 420-421 ; — low-intensity, 421 Enthesopathy, in fibromyalgia syndrome, 30 : RE 309—310 P medication interactions with, 424-426 Entrapment neuropathy, in fibromyalgia pain and fatigue in, 430-431 syndrome, 313 prescription for, 427-43] Cumulative Index 2002 / Rhe um Dis ¢ in N An 28 (2002) 1003-1030 principleso f, 421 —422 conditions overlapping with, 204, 206 pros and cons, 419-420 diagnosis of, 181-182, 212-213 strength training in, 427—428 differential diagnosis of, 212-213 32-434 lizziness in, 193, 281 —282 timing of, within treatment downward spiral in, 220 program, 422, 427 dysautonomia with. See Dysautonomia for idiopathic musculoskeletal pain endocrine dysfunction in, 190, 389-404 678-679 \ | ation of, 439 for inflammatory myopathy, 983 fatigue component, 262 368 — 369 Exercise testing inflammatory follow-up, 214-215 myopathy for exercise prescription Existential crisis, in fibromyalgia syndrome history in, 201 —209 9] 192 laboratory, 213-214 medical, 201-218 Extremities, abnormalities of, differential physical examination in, 209-214 diagnosis of, imaging in, 487—488 psychological, 204, 207, 219 Eye disorders, in juvenile dermatomyositis in. See Fatigue, in fibromyalgia 857 — 853 syndrome e in. See Headache, in fibromyalgia syndrome table bladder syndrome with, 193 abry disease, musculoskel 280, 410, 414—415 6 ible bowel syndrome with, 192 206. 280. 409~—410. 414 amilial Mediterranean fev patients, 6- 64% ne disease and, 411 —412, 414 iformation on, 44] amilial myositis, 894 disorders in tigue, in fibromyalgia y1 406 —407 nature of, 383-384 Causes t of, 437-446 442-443 ywhysiology of neuroendocrine perturbations 389 404 substance Pi n, 32 33] eedback, phy tient education on, 295—296 svndrom 6 370. 439-44] ognosis for, patient educational leve line immunodeti ind, 182-183 ndu] ctionYT chological factors in. See yndrome Psychological factors, in fibromyalgia syndrome of life in, evaluation of, 204 differential di 207 —208 484-487 idiologic evaluation of 213-214 Fibroblasts, cell cycle regulation of reflex sympathetic dystrophy in 408 — 409, 414 array analysiso f, 154—155 ing factors in, 206 an0y Fibromyalgia syndrome legs syndrome in, 206, 278 autoimmune disorders in, 409 361 —362. 410 chest pain in, 408-409, 413 eep disorders in. See Sleep disorde classification of, 202 fibromyalgia syndrome clinic for, 438 —439 subgroups of, 202 clinical features of, 383-384 substance P measurements in, 33 cold intolerance in, 193. 282 support groups for, 441 complexity of, 201 21U)Z? symptoms of, 202-206 conditions concomitant with, 192— 193, temporomandibular joint dysfunction 205, 208 —2 09, 280-282. 405-417 with, 281, 407, 413 Cumulative Index 2002 / Rheum D l im 28 (2002) 1003-1030 1011 treatment of, 181-199, 412—4 Fludrocortisone, for fibromyalgia syndrome aci ivanced, 442-443 373. 385 *sics for, 235 autoimmune conditions luoxetine, for fibron 173 975 371377 cognitive ; ood, inflammatory myopathy relate cognitive dysfunctior 102 —904 cold intolerance 3 complementary and alt 300) — 30] ankylosing tarsitis of, 546-54 dizziness. 193, 2 plantar fasciitis of, in fibromyalgia Scadinaaiaal . syndrome en\ddooccrriinnee ddyyssffuu nct |F orearm ischemic exercise n metabolic evaluation of myopathy exercise [or fibromyz ndrome inctional assessment, in inflammatory fatigue sympton myopathy, 946 369 headac > G Gait abnormalities, differential diagnosis of maging in, 488-490 globulin, for dermatomyositis, 593 Gamma-hydroxybutyrate, for fibromyalgia rome, 188—189. 278. 374 testinal manifestations disorder lenoch-Schénlein purpura, 639-640 flammatory ?—&33. 9904 rmacology 235-259 ! le dermatomyositis, 850 nacologic, 291—304 440 14 nd lifferences, in rheumatoid arthritis yte antiger nd, 24, 43, 47 yndrome en - for rheumatoid arthritis. See ont education f Rheumatoid arthri 1e therapy for 368 — 370. 436 pharmacologic, 261-290 2) pat t of tamilial Mediterranear 647 —648 principi. e of inclusion body myositis, 793 899 _9 00 f inflammatory myopathy, 893 —900 f issessmento f, 893 —894 fects of - » disorders chimerism in, 89 disorde 1s ‘ 177 978 familial myositis, 894 Ste : ce P iinnnh ibit TS human leukocyt? e antigens in 329-342 See under Human leukocyte temporomandibu 7 diyvssffuunnccttiioorn inclusion body, /93, 899—900 pprroocecsess s ffoorr., 44 3 \ non-HL. A genes in, 8m9n 8-899 tirr l ggering ftactors T-cell receptors in, 899 of juvenile dermatomyositis, 583 — 588, 56kd antigen, antibodies to 751 753 myopathy, 869, 883 of Kawasaki disease, 629 —630 Flexibility (raining, ft or fitti dromyali yndir ome of metabolic my» opathies 429 43030. . 443322--443344 of muscular dy7 strophy,: of osteoarthritis, 95-109 Fludarabine, for inflammatory myopathy of rheumatoid arthritis 988 Sd components of, 1 Cumulative Index 2002 / Rheum Dis Clin N Am 28 (2002) 1003—1030 gene therapy, 127-149 treatment of, 313-314, juvenile, 508-509 substance P inhibitors for, 337 outcome and, 39-58 prognosis and, 17-37 Health Assessment Questionnaire, i severity and, 59-78 inflammatory myopathy, 964 target tissue and, 79-94 Health-related quality of life of systemic lupus erythematosus, in inflammatory myopathy, 966-967 111-126 in pediatric patients, with arthritis, transcript array analysis in, 151-176 493-501 coping and, 496 Genome-wide scan, in osteoarthritis, 105— 107 definition of, 493-494 Genotoxicity, in inflammation, in rheumatoid health status domains in, 495-498 arthritis, 83-84 impact of, 498 methodologic issues in, 494 Gingival inflammation, in juvenile pain and, 496 dermatomyositis, 849 — 850 physical function and, 495 Glomerulonephritis psychosocial adjustment and, 497 in Henoch-Schénlein purpura, 640, rheumatoid, 514—515 643-644 social functioning and, 497-498 in microscopic polyangiitis, 646 Heart disorders in systemic lupus erythematosus, n fibromyalgia syndrome, 408, 413 561-563 in inflammatory myopathy, 833 Glycogenoses, 763, 766—767, 774 in juvenile dermatomyositis, 851 —852 Gold salts, for pediatric rheumatic Heart rate variability analysis, in fibromyalgia diseases, 469 syndrome, 380, 382—383 Gottron’s papules, in dermatomyositis, 827 Heliotrope rash, in dermatomyositis, 829 829, 844 841. 844 GR205171 (substance P inhibitor), for Hemophagocytic lymphohistiocytosis affective disorders, 336 syndrome, in juvenile rheumatoid arthritis, 518-519 Graft-versus-host disease inflammatory myopathy related to, Henoch-Schénlein purpura, in pediatric versus systemic sclerosis, 682 patients, 638 —644 intineutrophil cytoplasmic antibodies Granisetron, for fibromyalgia syndrome, in, 642 Granulomatosis arthritis and arthralgia in, 639 in sarcoidosis, 647 central nervous system involvement in Wegener’s granulomatosis, 644 n, 640 clinical features of, 638 Granzyme, in inflammatory myopathy, cutaneous manifestations of, 638 —6 39 810, 815 diagnosis of, 641 Growth disturbances epidemiology of, 638 in pediatric rheumatic diseases, 462-463 gastrointestinal involvement in, in systemic lupus erythematosus, 567 639-640 localized, in juvenile rheumatoid genitourinary involvement in, 640 arthritis, 516 kidney involvement in, 640, 643-644 pulmonary involvement in, 641 Growth hormone deficiency, in fibromyalgi treatment of, 642-644 syndrome, 190, 281, 360, 395-396 Hepatitis B inflammatory myopathy in, 909 juvenile dermatomyositis in, 585—586 Hand(s), mechanic’s, in dermatomyositis 849-850. 8 Hepatitis C, inflammatory myopathy in, 909 HLAs. See Human leukocyte antigens Headache in fibromyalgia syndrome, 206, 408, 411 Hormones, in systemic lupus erythematosus migraine, 280-281, 313-314, 411 development, 560-561